First Time Loading...
N

NextCure Inc
NASDAQ:NXTC

Watchlist Manager
NextCure Inc
NASDAQ:NXTC
Watchlist
Price: 1.6 USD 1.91% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

NXTC's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. [ Read More ]

The intrinsic value of one NXTC stock under the Base Case scenario is 3.88 USD. Compared to the current market price of 1.6 USD, NextCure Inc is Undervalued by 59%.

Key Points:
NXTC Intrinsic Value
Base Case
3.88 USD
Undervaluation 59%
Intrinsic Value
Price
N
Worst Case
Base Case
Best Case

Valuation Backtest
NextCure Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NXTC stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
NextCure Inc

Provide an overview of the primary business activities
of NextCure Inc.

What unique competitive advantages
does NextCure Inc hold over its rivals?

What risks and challenges
does NextCure Inc face in the near future?

Has there been any significant insider trading activity
in NextCure Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for NextCure Inc.

Provide P/S
for NextCure Inc.

Provide P/E
for NextCure Inc.

Provide P/OCF
for NextCure Inc.

Provide P/FCFE
for NextCure Inc.

Provide P/B
for NextCure Inc.

Provide EV/S
for NextCure Inc.

Provide EV/GP
for NextCure Inc.

Provide EV/EBITDA
for NextCure Inc.

Provide EV/EBIT
for NextCure Inc.

Provide EV/OCF
for NextCure Inc.

Provide EV/FCFF
for NextCure Inc.

Provide EV/IC
for NextCure Inc.

Show me price targets
for NextCure Inc made by professional analysts.

What are the Revenue projections
for NextCure Inc?

How accurate were the past Revenue estimates
for NextCure Inc?

What are the Net Income projections
for NextCure Inc?

How accurate were the past Net Income estimates
for NextCure Inc?

What are the EPS projections
for NextCure Inc?

How accurate were the past EPS estimates
for NextCure Inc?

What are the EBIT projections
for NextCure Inc?

How accurate were the past EBIT estimates
for NextCure Inc?

Compare the revenue forecasts
for NextCure Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of NextCure Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of NextCure Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of NextCure Inc compared to its peers.

Compare the P/E ratios
of NextCure Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing NextCure Inc with its peers.

Analyze the financial leverage
of NextCure Inc compared to its main competitors.

Show all profitability ratios
for NextCure Inc.

Provide ROE
for NextCure Inc.

Provide ROA
for NextCure Inc.

Provide ROIC
for NextCure Inc.

Provide ROCE
for NextCure Inc.

Provide Gross Margin
for NextCure Inc.

Provide Operating Margin
for NextCure Inc.

Provide Net Margin
for NextCure Inc.

Provide FCF Margin
for NextCure Inc.

Show all solvency ratios
for NextCure Inc.

Provide D/E Ratio
for NextCure Inc.

Provide D/A Ratio
for NextCure Inc.

Provide Interest Coverage Ratio
for NextCure Inc.

Provide Altman Z-Score Ratio
for NextCure Inc.

Provide Quick Ratio
for NextCure Inc.

Provide Current Ratio
for NextCure Inc.

Provide Cash Ratio
for NextCure Inc.

What is the historical Revenue growth
over the last 5 years for NextCure Inc?

What is the historical Net Income growth
over the last 5 years for NextCure Inc?

What is the current Free Cash Flow
of NextCure Inc?

Financials

Balance Sheet Decomposition
NextCure Inc

Current Assets 112.7m
Cash & Short-Term Investments 108.3m
Other Current Assets 4.4m
Non-Current Assets 15.3m
PP&E 13.4m
Other Non-Current Assets 1.9m
Current Liabilities 6.9m
Accounts Payable 2.3m
Accrued Liabilities 4.6m
Non-Current Liabilities 6.7m
Other Non-Current Liabilities 6.7m
Efficiency

Earnings Waterfall
NextCure Inc

Revenue
0 USD
Operating Expenses
-67.6m USD
Operating Income
-67.6m USD
Other Expenses
4.9m USD
Net Income
-62.7m USD

Free Cash Flow Analysis
NextCure Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

NXTC Profitability Score
Profitability Due Diligence

NextCure Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

15/100
Profitability
Score

NextCure Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

NXTC Solvency Score
Solvency Due Diligence

NextCure Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
49/100
Solvency
Score

NextCure Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NXTC Price Targets Summary
NextCure Inc

Wall Street analysts forecast NXTC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NXTC is 5.1 USD with a low forecast of 3.03 USD and a high forecast of 8.4 USD.

Lowest
Price Target
3.03 USD
89% Upside
Average
Price Target
5.1 USD
219% Upside
Highest
Price Target
8.4 USD
425% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

NXTC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NXTC Price
NextCure Inc

1M 1M
+13%
6M 6M
+24%
1Y 1Y
+3%
3Y 3Y
-82%
5Y 5Y
-92%
10Y 10Y
-92%
Annual Price Range
1.6
52w Low
1.03
52w High
2.49
Price Metrics
Average Annual Return -4.86%
Standard Deviation of Annual Returns 124.26%
Max Drawdown -99%
Shares Statistics
Market Capitalization 44.6m USD
Shares Outstanding 27 903 000
Percentage of Shares Shorted 3.63%

NXTC Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

NextCure Inc

Country

United States of America

Industry

Biotechnology

Market Cap

44.6m USD

Dividend Yield

0%

Description

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 86 full-time employees. The company went IPO on 2019-05-09. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO), platform, the Company is studying various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its product candidates include NC318, NC410, NC762 and NC 525. NC318, is an immunomedicine against a novel immunomodulatory protein called Siglec-15. NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor. NC762, is an immunomedicine targeting an immunomodulatory molecule called human B7 homolog 4 protein. NC525, is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia.

Contact

MARYLAND
Beltsville
9000 Virginia Manor Rd Ste 200
+12403994900.0
http://www.nextcure.com/

IPO

2019-05-09

Employees

86

Officers

Co-Founder, CEO, President & Director
Mr. Michael S. Richman MSBA
Chief Scientific Officer
Dr. Solomon Langermann Ph.D.
Chief Medical Officer
Dr. Han Myint FACP, M.D.
Co-Founder & Chairman of Scientific Advisory Board
Dr. Lieping Chen M.D., Ph.D.
Chief Financial Officer
Mr. Steven P. Cobourn CPA
Chief Operating Officer
Dr. Timothy Mayer Ph.D.
Show More
General Counsel
Mr. Kevin G. Shaw
Vice President of Human Resources
Ms. Stacy Rollinger
Senior Vice President of Development & Manufacturing
Mr. Sourav Kundu Ph.D.
Senior Vice President of Business Development
Dr. Sebastien Maloveste
Show Less

See Also

Discover More
What is the Intrinsic Value of one NXTC stock?

The intrinsic value of one NXTC stock under the Base Case scenario is 3.88 USD.

Is NXTC stock undervalued or overvalued?

Compared to the current market price of 1.6 USD, NextCure Inc is Undervalued by 59%.